Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder
Abstract
:1. Introduction
2. Materials and Methods
Interventions
3. Results
4. Discussion
Acknowledgments
Author Contributions
Conflicts of Interest
References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®); American Psychiatric Pub: Washington, DC, USA, 2013. [Google Scholar]
- Lecavalier, L. Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. J. Autism Dev. Disord. 2006, 36, 1101–1114. [Google Scholar] [CrossRef] [PubMed]
- Tonge, B.J.; Einfeld, S.L. Psychopathology and intellectual disability: The Australian child to adult longitudinal study. Int. Rev. Res. Men. Retard. 2003, 26, 61–91. [Google Scholar]
- Samadi, S.A.; Mahmoodizadeh, A.; McConkey, R. A national study of the prevalence of autism among five-year-old children in Iran. Autism 2012, 16, 5–14. [Google Scholar] [CrossRef] [PubMed]
- Warren, Z.; Veenstra-VanderWeele, J.; Stone, W.; Bruzek, J.L.; Nahmias, A.S.; Foss-Feig, J.H.; Jerome, R.N.; Krishnaswami, S.; Sathe, N.A.; Glasser, A.M. Therapies for Children with Autism Spectrum Disorders; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2011. [Google Scholar]
- McDougle, C.; Scahill, L.; McCracken, J.; Aman, M.; Tierney, E.; Arnold, L.; Freeman, B.; Martin, A.; McGough, J.; Cronin, P. Research units on pediatric psychopharmacology (RUPP) autism network. Background and rationale for an initial controlled study of risperidone. Child Adolesc. Psychiatr. Clin. N. Am. 2000, 9, 201–224. [Google Scholar] [PubMed]
- Myers, S.M. The status of pharmacotherapy for autism spectrum disorders. Expert Opin. Pharmacother. 2007, 8, 1579–1603. [Google Scholar] [CrossRef] [PubMed]
- Shea, S.; Turgay, A.; Carroll, A.; Schulz, M.; Orlik, H.; Smith, I.; Dunbar, F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114, e634–e641. [Google Scholar] [CrossRef] [PubMed]
- McCracken, J.T.; McGough, J.; Shah, B.; Cronin, P.; Hong, D.; Aman, M.G.; Arnold, L.E.; Lindsay, R.; Nash, P.; Hollway, J. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 2002, 347, 314–321. [Google Scholar] [CrossRef] [PubMed]
- Mccracken, J.; Mcgough, J.; Shah, B. Research units on pediatric psychopharmacology autism network, risperidone in childrenwith autism and serious behavior problems. J. Pediatr. 2003, 142, 86–87. [Google Scholar]
- Mohammad Zaheri, F.; Rafiei, S.M.; Rezaei, M.; Bakhshi, E. Effect of pivotal response treatment on social skill of 6–11 years old autistic children of hamedan. Pajouhan Sci. J. 2013, 11, 16–21. [Google Scholar]
- Mohammadzaheri, F.; Koegel, L.K.; Rezaee, M.; Rafiee, S.M. A randomized clinical trial comparison between pivotal response treatment (PRT) and structured applied behavior analysis (ABA) intervention for children with autism. J. Autism Dev. Disord. 2014, 44, 2769–2777. [Google Scholar] [CrossRef] [PubMed]
- Mohammadzaheri, F.; Koegel, L.K.; Rezaei, M.; Bakhshi, E. A randomized clinical trial comparison between pivotal response treatment (PRT) and adult-driven applied behavior analysis (ABA) intervention on disruptive behaviors in public school children with autism. J. Autism Dev. Disord. 2015, 45, 2899–2907. [Google Scholar] [CrossRef] [PubMed]
- Mohammad-Zaheri, F.; Rezaei, M.; Rafi’ei, M.; Bakhshi, E.; Gharib, M. Effect of pivotal response treatment method on initiation skill in children with autism. Arch. Rehabil. 2014, 15, 72–77. [Google Scholar]
- Perry, A.; Condillac, R. Evidence-Based Practices for Children and Adolescents with Autism Spectrum Disorders: Review of the Literature and Practice Guide; Children’s Mental Health Ontario: Toronto, ON, Canada, 2003. [Google Scholar]
- Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am. J. Psychiatry 2005, 162, 1361–1369. [Google Scholar]
- Akhondzadeh, S.; Fallah, J.; Mohammadi, M.-R.; Imani, R.; Mohammadi, M.; Salehi, B.; Ghanizadeh, A.; Raznahan, M.; Mohebbi-Rasa, S.; Rezazadeh, S.-A. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34, 32–36. [Google Scholar] [CrossRef] [PubMed]
- Nilipour, R. Farsi Aphasia Test; Iran University of Medical Sciences Publisher: Tehran, Iran, 1993; Volume 1372. [Google Scholar]
- Guy, W. The Clinical Global Impression Scale. The Ecdeu Assessment Manual for Psychopharmacology Revised; Publ. No. ADM 76-338; US Department of Health Education, and Welfare: Rockville, MD, USA, 1976; Volume DHEW, pp. 218–222. [Google Scholar]
- Scahill, L.; Aman, M.G.; McDougle, C.J.; Arnold, L.E.; McCracken, J.T.; Handen, B.; Johnson, C.; Dziura, J.; Butter, E.; Sukhodolsky, D. Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J. Autism Dev. Disord. 2009, 39, 720–729. [Google Scholar] [CrossRef] [PubMed]
- Koegel, LK. Pivotal Response Treatment®: Using Motivation as a Pivotal Response; Behavior Management Student Organization: Santa Barbara, CA, USA, 2011. [Google Scholar]
- Nelson, K.E.; Camarata, S.M.; Welsh, J.; Butkovsky, L.; Camarata, M. Effects of imitative and conversational recasting treatment on the acquisition of grammar in children with specific language impairment and younger language-normal children. J. Speech Lang. Hear. Res. 1996, 39, 850–859. [Google Scholar] [CrossRef]
- Harper, C.B.; Symon, J.B.; Frea, W.D. Recess is time-in: Using peers to improve social skills of children with autism. J. Autism Dev. Disord. 2008, 38, 815–826. [Google Scholar] [CrossRef] [PubMed]
- Aman, M.G.; Mcdougle, C.J.; Scahill, L.; Handen, B.; Arnold, L.E.; Johnson, C.; Stigler, K.A.; Bearss, K.; Butter, E.; Swiezy, N.B. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48, 1143–1154. [Google Scholar] [CrossRef] [PubMed]
- McDougle, C.J.; Scahill, L.; Aman, M.G.; McCracken, J.T.; Tierney, E.; Davies, M.; Arnold, L.E.; Posey, D.J.; Martin, A.; Ghuman, J.K. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am. J. Psychiatry 2005, 162, 1142–1148. [Google Scholar] [CrossRef] [PubMed]
- Campbell, M.; Anderson, L.T.; Meier, M.; Cohen, I.L.; Small, A.M.; Samit, C.; Sachar, E.J. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J. Am. Acad. Child Psychiatry 1978, 17, 640–655. [Google Scholar] [CrossRef]
- De Giacomo, A.; Craig, F.; Terenzio, V.; Coppola, A.; Campa, M.G.; Passeri, G. Aggressive behaviors and verbal communication skills in autism spectrum disorders. Glob. Pediatr. Health 2016, 3, 2333794X16644360. [Google Scholar] [CrossRef] [PubMed]
Child Attending |
The speech/language pathologists (SLP) must attract child’s attention before provoking a chance. |
Obvious Chance |
The question/education/opportunity to respond must be clear and suitable for the task. |
Child Choice |
The SLP should follow the child’s choice with tasks and actions. If child is not showing interest in the present task, SLP should effort to alter the practice. |
Keep Tasks |
The SLP should combine tasks the child can already complete with new tasks. |
Conditional |
Reinforcement must be depending on child’s behavior. The SLP’s response must be contingent upon the child’s response. |
Natural |
Reinforcement should be natural or right associated to the favorite behavior. |
Depending on Challenges |
Any target-directed effort to respond to questions, guidelines, or chances should be reinforced. |
Variable | RIS Group (n = 17) Mean ± SD | PRT + RIS Group (n = 17) Mean ± SD | p |
---|---|---|---|
Age | 148.94 ± 29.41 | 144.70 ± 37.58 | 0.911 |
MLU | 3.54 ± 0.60 | 3.23 ± 0.80 | 0.212 |
Age of onset | 28.72 ± 4.21 | 29.68 ± 5.80 | 0.588 |
Weight | 44.35 ± 12.31 | 43.82 ± 14.93 | 0.799 |
Irritability | 2.72 ± 23.23 | 4.86 ± 23.05 | 0.897 |
Lethargy/social withdrawal | 5.16 ± 30.41 | 28.52 ± 5.00 | 0.288 |
Hyperactivity/noncompliance | 8.65 ± 22.94 | 8.75 ± 19.58 | 0.27 |
Stereotypic behavior | 3.05 ± 17.23 | 4.45 ± 15.05 | 0.107 |
Inappropriate speech | 1.76 ± 9.00 | 1.67 ± 9.94 | 0.285 |
Variable | RIS Group (n = 17) Mean ± SD | PRT + RIS Group (n = 17) Mean ± SD | Mean Difference | p |
---|---|---|---|---|
MLU | 0.591 ± 3.60 | 0.832 ± 4.23 | 0.930 | ≤0.0001 |
Irritability | 2.10 ± 13.76 | 4.80 ± 13.41 | 0.247 | 0.806 |
Lethargy/social withdrawal | 4.84 ± 26.94 | 6.49 ± 20.88 | 4.299 | 0.001 |
Hyperactivity/noncompliance | 6.39 ± 14.64 | 6.05 ± 12.88 | 0.431 | 0.631 |
Stereotypic behavior | 2.34 ± 9.41 | 4.52 ± 8.05 | 0.002 | 0.999 |
Inappropriate speech | 5.171 ± 94 | 4.471 ± 84 | 1.514 | 0.001 |
Variable | Baseline Mean ± SD | Endpoint Mean ± SD | Follow-Up Mean ± SD | p |
---|---|---|---|---|
Irritability | ||||
RIS | 2.72 ± 23.23 | 2.10 ± 13.76 | 1.39 ± 17.76 | ≤0.0001 |
RIS + PRT | 23.05 ± 4.86 | 13.41 ± 4.80 | 16.82 ± 4.27 | |
Lethargy/social withdrawal | ||||
RIS | 30.41 ± 5.16 | 26.94 ± 4.84 | 27.94 ± 4.86 | ≤0.0001 |
RIS + PRT | 28.52 ± 5.00 | 20.88 ± 6.49 | 21.35 ± 5.33 | |
Hyperactivity/noncompliance | ||||
RIS | 22.94 ± 8.65 | 14.46 ± 6.39 | 18.11 ± 7.00 | ≤0.0001 |
RIS + PRT | 8.75 ± 19.58 | 6.05 ± 12.88 | 15.35 ± 6.48 | |
Stereotypic behavior | ||||
RIS | 17.23 ± 3.05 | 9.41 ± 2.38 | 12.47 ± 2.06 | ≤0.0001 |
RIS + PRT | 15/05 ± 4.45 | 8/05 ± 4.52 | 10/94 ± 4.00 | |
Inappropriate speech | ||||
RIS | 9.00 ± 1.76 | 5.17 ± 1.94 | 6.58 ± 1.87 | ≤0.0001 |
RIS + PRT | 9.94 ± 1.67 | 4/47 ± 1.84 | 6.64 ± 1.72 |
Variables | RIS Group (n = 17) N (%) | PRT + RIS Group (n = 17) N (%) | p |
---|---|---|---|
Increased appetite | 4 (23.5) | 3(17.6) | 0.671 |
Nausea | 2 (11.8) | 2(11.8) | 1 |
Urinary problems | 3 (17.6) | 2(11.8) | 0.682 |
Increased weight | 2 (11.8) | 2(11.8) | 1 |
Sedation | 1 (5.9) | 1(5.9) | 1 |
Dizziness | 1 (5.9) | 2(11.8) | 0.545 |
Constipation | 3 (17.6) | 3(17.6) | 1 |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rezaei, M.; Moradi, A.; Tehrani-Doost, M.; Hassanabadi, H.; Khosroabadi, R. Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder. Children 2018, 5, 19. https://doi.org/10.3390/children5020019
Rezaei M, Moradi A, Tehrani-Doost M, Hassanabadi H, Khosroabadi R. Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder. Children. 2018; 5(2):19. https://doi.org/10.3390/children5020019
Chicago/Turabian StyleRezaei, Mohammad, AliReza Moradi, Mehdi Tehrani-Doost, HamidReza Hassanabadi, and Reza Khosroabadi. 2018. "Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder" Children 5, no. 2: 19. https://doi.org/10.3390/children5020019
APA StyleRezaei, M., Moradi, A., Tehrani-Doost, M., Hassanabadi, H., & Khosroabadi, R. (2018). Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder. Children, 5(2), 19. https://doi.org/10.3390/children5020019